Tirofiban (INN, trade name Aggrastat) is an antiplatelet drug. It belongs to a class
of antiplatelet named glycoprotein IIb/IIIa inhibitors. Tirofiban is the first drug ...
Jul 6, 2016 ... AGGRASTAT contains tirofiban hydrochloride, a non-peptide antagonist of the
platelet GP IIb/IIIa receptor, which inhibits platelet aggregation.
Easy to read patient leaflet for tirofiban. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Professional guide for Tirofiban Hydrochloride. Includes: pharmacology,
pharmacokinetics, contraindications, interactions, adverse reactions and more.
(1)Adis International Limited, Auckland, New Zealand. firstname.lastname@example.org.
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa
AGGRASTAT (Tirofiban) drug information & product resources from MPR
including dosage information, educational materials, & patient assistance.
Consumer information about the medication TIROFIBAN - INJECTION (Aggrastat)
, includes side effects, drug interactions, recommended dosages, and storage ...
Welcome to AGGRASTAT.com. The information contained here is intended for.
HEALTHCARE PROFESSIONALS ONLY. For Non-US Healthcare Professionals
Aggrastat Solution: 1 ml of solution for infusion contains 56 micrograms of
tirofiban hydrochloride monohydrate which is equivalent to 50 micrograms
Jun 15, 2015 ... Tirofiban is indicated for the prevention of early myocardial infarction in adult
patients presenting acute coronary syndromes without ST ...